Patents by Inventor Junran YANG

Junran YANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FUSED BICYCLIC DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT, CRYSTAL FORM THEREOF AND PREPARATION METHOD THEREFOR
    Publication number: 20250145641
    Abstract: Provided are a fused bicyclic derivative, a pharmaceutically acceptable salt, a crystal form thereof and a preparation method therefor. Specifically, provided are a hydrochloride, a mesylate, an acetate and a tartrate of the compound of formula (I), and a preparation method therefor and a crystal form thereof.
    Type: Application
    Filed: September 16, 2022
    Publication date: May 8, 2025
    Inventors: Tingting SHANG, Miaomiao ZHAO, Junran YANG, Zhenxing DU, Lin WANG, Qiyun SHAO, Jun FENG, Feng HE
  • PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTALLINE FORM OF GLP-1 RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR
    Publication number: 20250049777
    Abstract: Provided are a pharmaceutically acceptable salt and a crystalline form of a GLP-1 receptor agonist and a preparation method therefor. Specifically, provided are a pharmaceutically acceptable salt and a crystalline form of a compound 2-((4-((S)-3-(4-chloro-2-fluorophenyl)-2,3-dihydrobenzo[b][1,4]dioxane-5-yl)piperidin-1-yl)methyl)-1-(((S)-oxe-tane-2-yl)methyl)-1H-benzo[d]imidazole-6-formic acid.
    Type: Application
    Filed: December 23, 2022
    Publication date: February 13, 2025
    Inventors: Weidong LU, Gujun XU, Junran YANG, Qiyun SHAO, Zhenxing DU, Jun FENG, Feng HE
  • CRYSTALLINE FORM OF GLP-1 RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR
    Publication number: 20250049778
    Abstract: A crystalline form of a GLP-1 receptor agonist and a preparation method therefor. The agonist is a compound 2-((4-((S)-3-(4-chloro-2-fluorophenyl)-2,3-dihydrobenzo[b][1,4]dioxane-5-yl)piperidin-1-yl)methyl)-1-(((S)-oxe-tan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid.
    Type: Application
    Filed: December 23, 2022
    Publication date: February 13, 2025
    Inventors: Gujun Xu, Weldong Lu, Junran Yang, Zhenxing Du, Qiyun Shao
  • SALT TYPES OF TRICYCLIC TETRAHYDRO ISOQUINOLINE DERIVATIVE
    Publication number: 20240374581
    Abstract: The present disclosure relates to salt types of a tricyclic tetrahydro isoquinoline derivative. Specifically, the present disclosure relates to different salt types of a compound as represented by formula (I) and a preparation method therefor. The salt types of the compound of formula (I) provided in the present disclosure have good stability and can be better used for clinical treatment.
    Type: Application
    Filed: July 8, 2022
    Publication date: November 14, 2024
    Inventors: Lina JIA, Lin WANG, Qiyun SHAO, Jun FENG, Junran YANG, Zhenxing DU
  • PHARMACEUTICALLY ACCEPTABLE SALT OF PYRAZOLOHETEROARYL DERIVATIVE AND CRYSTAL FORM THEREOF
    Publication number: 20240262823
    Abstract: The present disclosure relates to a pharmaceutically acceptable salt of a pyrazoloheteroaryl derivative and a crystal form thereof. In particular, the present disclosure relates to a pharmaceutically acceptable salt of a compound represented by formula (I), and a crystal form thereof. The novel crystal form of the present disclosure has good physical and chemical properties.
    Type: Application
    Filed: May 20, 2022
    Publication date: August 8, 2024
    Inventors: Jiaqi YAO, Junran YANG, Zhenxing DU
  • Crystal form of oxopicolinamide derivative and preparation method therefor
    Patent number: 11299462
    Abstract: Provided are a crystal form of an oxopicolinamide derivative and a preparation method therefor. In particular, provided are crystal forms A, B, C, D, E, and F of a compound as shown in formula (I) and a preparation method therefor. Crystal forms A, B, C, D, E, and F of the compound of formula (I) obtained in the present disclosure have good crystal stability and chemical stability, and can be better used in clinical treatment.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: April 12, 2022
    Assignee: Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Junran Yang, Lin Wang, Qiyun Shao, Zhenxing Du, Likun Wang
  • CRYSTAL FORM OF MALEATE OF TYROSINE KINASE INHIBITOR AND PREPARATION METHOD THEREFOR
    Publication number: 20210355109
    Abstract: Provided are a crystal form of a maleate of a tyrosine kinase inhibitor and a preparation method therefor. Specifically, provided are I crystal form, a II crystal form, a III crystal form, a IV crystal form and a V crystal form of the compound as shown in formula (I) and a preparation method therefor. The new crystal form has a good stability, thereby making same better to use in clinical treatments.
    Type: Application
    Filed: October 21, 2019
    Publication date: November 18, 2021
    Applicant: JIANGSU HENGRUI MEDICINE CO., LTD.
    Inventors: Zhenjun QIU, Quanliang ZHANG, Yanli WEI, Yongxing CAO, Junran YANG, Yahui MA, Zhenxing DU, Jie WANG
  • CRYSTAL FORM OF OXOPICOLINAMIDE DERIVATIVE AND PREPARATION METHOD THEREFOR
    Publication number: 20200385353
    Abstract: Provided are a crystal form of an oxopicolinamide derivative and a preparation method therefor. In particular, provided are crystal forms A, B, C, D, E, and F of a compound as shown in formula (I) and a preparation method therefor. Crystal forms A, B, C, D, E, and F of the compound of formula (I) obtained in the present disclosure have good crystal stability and chemical stability, and can be better used in clinical treatment.
    Type: Application
    Filed: February 26, 2019
    Publication date: December 10, 2020
    Inventors: Junran YANG, Lin WANG, Qiyun SHAO, Zhenxing DU, Likun WANG